Medicinal Chemistry Faculty

Duane D. Miller, Ph.D. Harriett S. Van Vleet Professor Department Chair and Associate Dean  Office location:   847 Monroe Ave. Room 327A Memphis, TN 38163 (901)448-6026 (901)448-6828 fax Current Office Hours: by appointment Email: dmiller@utmem.edu CURRICULUM VITAE The Miller's Group

B.S. in Pharmacy, University of Kansas, 1966
Ph.D. (Medicinal Chemistry), University of Washington, 1969

I. EDUCATIONAL PROGRAMS

Year        Course No.     Course (Credit)         Your Contribution                     Semester

P-1               112         Medicinal Chemistry         Instructor (24)                         Fall 1997-present
Graduate      612         Medicinal Chemistry         Instructor (10)                         Fall 1997-present
Graduate      812         Medicinal Chemistry         Instructor (15)                         Spring 1998 -present
Graduate      801         Graduate Ethics                 Instructor (2)                           Spring 1998 -present

II. RESEARCH

• Cocaine Antagonists-We have initiated a new project with Dr. Mark Sonders to find new agents to block the craving for cocaine.
• Beta-3 Antagonists - The synthesis of potential beta-3 antagonists is now underway in our laboratory. We have prepared some new compounds that should help to find selective antagonists of the beta-3 adrenergic receptor. Such agents would be valuable pharmacological tools since no such selective type compounds now exsist.
• Antiobesity Beta-3 Adrenergic Stimulants- The synthesis of new analogs of Trimetoquinol is directed at making new drugs that would be effective in the treatment of obesity. These are reversible analogs of trimetoquinol that have shown the ability to break down adipose tissue and generate heat.
• Imidazoline Analogs as Probes of a- Adrenergic Receptors- In this research area we have been preparing affinity labels that bind to adrenergic receptors, imidazoline receptors and calcium channel receptors. We have found a prototype molecule that we call IBI that interacts in aorta with only calcium channels and this molecule produces only long acting agonist activity by activating calcium channels. We have prepare over 20 new analogs and have found the points that are critical for binding to the calcium channel receptor. We have also noted that some of these compounds are very active in binding to imidazoline receptors in the brain. They have the potential of being a new class of antihypertensive agents that act on imidazoline receptors.
• Design and Synthesis of a2-Adrenergic Agonists With Central Nervous System Activity-This project involves the synthesis of conformationally restricted analogs of medetomidine. This research will provide insight into whether or not we can separate the sedative from the antihypertensive effects in the central nervous system. We have completed the synthesis of two analogs in this search at the present time.
• Irreversible Antiandrogens for the Treatment of Prostate Cancer- In collaboration with Dr. Jim Dalton in our department we are preparing new synthetic analogs of casodex to see if we can find new drugs for the treatment of prostate cancer.
• Radioiodinated Antiandrogens For Prostate Imaging- This is collaboration with Dr. Jim Dalton and Dr. Bill Purcell in an attempt to find better imaging agents than are presently available for examining prostate cancer.
• Aldose Reductase Inhibitors- This is in collaboration with Dr. Isaac Donkor. We are attempting to find new irreversible inhibitors of the enzyme aldose reductase. These new agents would be useful in the treatment of diabetic complications.
• New Lipid agents- This is a poject that is in collaboration with Dr. GaborTigyi in the Department of Physiology. These are new agents that regualate apoptosis with the potential for the treatment of cancer.
• New Nonsteroidal Androgen Agonists. These agents are being examined as potential agents for androgen replacement therapy and male contraception.
• ARDS Research- We are examining the gluccocorticoid receptors and their involement in ARDS. We will begin to design new drugs to overcome some of the problems with therapy in ARDS patients.
• Mentor- Serving to help Dr. Isaac Donkor with his research to find new protease inhibitors of calpain.

            A.  Awarded/Funded Research Projects Initiated in 2005-2006

 Number: R01 CA 92160-05
Principal Investigator: Gabor Tigyi principal investigator, Duane Miller CO-PI
Dates: 08/01/06-07/31/11
Source: National Institutes of Health
Title: Ligand Recognition by Phospholipid Growth Factor Receptors
Annual Direct Cost: $250, 000 (Total direct $1,250,000)
Current Percent Effort: 2%
Summary : The goal of this research is to understand how receptor structure defines selectivity for LPA and to design new agents for the LPA receptors.

Number: R073621168 ED Laboratories Research Contract
Principal Investigator: Duane Miller, Eldon Geisert, and Ryan Yates Co-PI
Dates: 04/01/05-03/31/06
Source: ED Laboratory
Title: THI in the treatment of Glioma
Annual Direct Cost: $180,000
Current Percent Effort: 2%
Summary : The goal of this research is to find a new drug for the treatment of glioma.

 Number: R073621172  GTx Service Contract
Principal Investigator: Duane Miller PI
Dates: 02/01/2005-1/31/2006
Source: GTx Bioanalytical contract
Title: New SARMS
Annual Direct Cost:: $142,982.00
Current Percent Effort: 2%
Summary : The goal of this research is to make compounds that we currently have in patents.

        B.  Awarded/Funded Research Projects Continued from Previous Years 

Active Support for Duane Miller

Number: R01 DK 065227-03
Principal Investigator: Duane Miller
Dates: 08/15/03 – 06/30/07
Source: National Institutes of Health
Title: Novel Irreversible Nonsteroidal SARMs for Prostate Cancer
Annual Direct Cost: $252,960
Current Percent Effort: 12%
Summary : We are examining the action of irreversibly acting agents that have nonsteroidal SARM structure in the treatment of prostate cancer. This project is focused on designing irreversible agents that will bind to the androgen receptor based upon compounds with reversible binding to the androgen receptor. These agents could be of value in treating prostate cancer.

 Number: R01 DK059800-06
Principal Investigator: Jim Dalton, subcontract to Duane Miller
Dates: 09/01/05-08/31/09
Source: National Institutes of Health, NCI
Title: Pharmacology of Nonsteroidal Androgen Receptor Ligands
Annual Direct Cost: $62,279
Current Percent Effort: 5%
Summary : The overall goal of this project is to develop structure-activity relationships based on the physicochemical and pharmacokinetic properties of nonsteroidal SARM drugs.

Number: NIH HL67479-05
Principal Investigator: John Buolamwini minority faculty, Duane Miller mentor
Dates: 09/01/00-08/31/06
Source: National Institutes of Health
Title: NBMPR Binding Site of the Human ES Adensosi ne Transporter
Annual Direct Cost: $147,949
Current Percent Effort: 5%
Summary : This project is a study of the inhibitor sensitive nucleoside transporters as potential candidates for ischemic heart and brain diseases.

Number: R01 CA 92160-05
Principal Investigator: Gabor Tigyi principal investigator, Duane Miller investigator
Dates: 08/01/06-07/31/11
Source: National Institutes of Health
Title: Ligand Recognition by Growth Factor Receptors
Annual Direct Cost: $207,500
Current Percent Effort: 5%
Summary : The goal of this research is to understand how receptor structure defines selectivity for LPA.

 IV.      SCHOLARLY ACTIVITIES 

 A.         Journal Articles (Published/In-Print)

229.     V.I. Nikulin, I. M. Rakov, J. E. De Los Angeles, R. C. Mehta, L. Y. Boyd, D. R. Feller, and D. D. Miller, 1-Benzyl-1,2,3,4-tetrahydroisoquinoline-6,7-diols as Novel Affinity and Photoaffinity Probes for b-Adrenoceptor Subtypes, Bioorg. Med. Chem., 14,402-408 (2006).

 230.    W. Gao, J.S. Johnston, D.D. Miller and J.T. Dalton, Interspecies Difference in Pharmacokinetics and Metabolism of S-3-(4-acetylamino-phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluromethylphenyl)-propionamide:  The Role of N-acetyltransferase, Drug Metab.Dispos., 34, 254-60, (2006).

231.     W. Gao, Z. Wu, C.E. Bohl, J. Yang, D.D. Miller and J.T. Dalton, Characterization of the In Vitro Metabolism of Selective Androgen Receptor Modulator Using Human, Rat, and Dog Liver Enzyme Preparations, Drug Metab. Dispos., 34, 243-53 (2006).

232.     D. Wu, Z. Wu, J. Yang, V.A. Nair, D.D. Miller and J.T. Dalton, Pharmacokinetics and Metabolism of a Selective Androgen Receptor Modulator in Rats:  Implication of Molecular Properties and Intensive Metabolic Profile to Investigate Ideal Pharmacokinetic Characteristics of Propanamide in Preclinical Study, Drug Metab. Dispos., 34, 483-94 (2006).

233.         J. Yang, C.E. Bohl, V.A. Nair, S.M. Mustafa, S.S. Hong, D.D. Miller and J.T. Dalton, Preclinical Pharmacology of Nonsteroidal Ligand for Androgen Receptor-Mediated Imaging of Prostate Cancer, J. Pharmacol. Exp. Ther., 317, 402-8 (2006).

234.         G. G. Durgam, R. Tsukahara, N. Markarova, M. D. Walker, Y. Fujiwara, K. R. Pigg, D. L. Baker, V. M. Sardar, A. L. Parrill, G. Tigyi, and D. D. Miller,  Synthesis and Pharmacological Evaluation of Second-generation Phosphatidic Acid Derivatives as Lysophosphatidic Acid Receptor Ligands., Bioorg. Med. Chem. Lett., 16(3), 633-640 (2006).

235.         V. Gududuru, K. Zeng, R. Tsukahara, N. Markarova, Y. Fjiwara, K. R. Pigg, D. L. Baker, G. Tigyi, and D. D. Miller, Identification of Darmstoff Analogs as Selective Agonists and Antagonists of Lysophosphatidic Acid Receptors, Bioorg. Med. Chem. Lett., 16(2), 451-456 (2006).

236.         R. Patil, W. Li, C. R. Ross,II, E. Kraka, D. Cremer, M. L. Mohler, J. T. Dalton, and D. D. Miller, Cesium Fluoride and tetra-n-butylammonium Fluoride Mediated 1,4-N-O Shift of Disubstituted Phenyl Ring of a Bicalutamide Derviative, Tet. Lett., 47,3941-3944 (2006).

237.         V. A. Nair, S. M. Mustafa, M. L. Mohler, J. T. Dalton and D. D. Miller, Synthesis of Oxazolidinedione Derived Bicalutamide Analogs, Tet. Lett., 47,3953-3955 (2006).

238.         M. L. Mohler, V. A. Nair, D. J. Hwang, I. M. Rakov, R. Patil, and D. D. Miller, Expert Opinion on Therapeutic Patents, 15(11), 1565-1585 (2005).

239.         D. J. Hwang, J. Yang, H. Xu, I. M. Rakov, M. L. Mohler, J. T. Dalton, and D. D. Miller, Arylisothiocyanato Selective Androgen Receptor Modulators (SARMs) for Prostate Cancer, Bioorg. Med. Chem. 14, 6525-6538 (2006).

240.         M. L. Molhler, G. Kang, S. Hong, R. Patil, O. V. Kirichenko, W. Li, I. M. Rakov, E. E. Geisert, and D. D. Miller, Disovery of Antiglioma Acitivity of Biaryl 1,2,3,4 Tetrahydroisoquinoline Derviatives and Conformationally Flexible Analogs, J. Med. Chem.,19, 5845-5848(2006).

241.         S. A. Bavadekar, G. Ma, S. M. Mustafa, B.M. Moore, D. D. Miller and D. R. Feller, Tethered Yohimbine Analogs as Selective Human a2C-Adrenergic Receptor Ligands, J. Phamacol. Exp. Ther. 319(2), 739-748 (2006).

242.         M. A. Perera, D. Yin, D. Wu, K. K. Chan, D. D. Miller and J. Dalton, In vivo Metabolism and Final Disposition of a Novel Nonsteroidal Androgen in Rats and Dogs, Drug Metab. Dispos. 34, 1713-1721 (2006).

243.         D. Wu, Z. Wu, J. Yang, V. A. Nair, D. D. Miller and J. T. Dalton, Pharmacokinetics and Metabolism of a Selective Androgen Receptor Modulator in Rats: Implication of Molecular Properties and Intensive Metabolic Profile to Investigate Ideal Pharmacokinetic Characteristics of a Propanamide in Preclinical Study, Drug Metab. Dispos. 34, 483-494 (2006).

244.         J. D. Kearbey, W. Gao, R. Narayanan, S. J. Fisher, D. Wu, D. D. Miller, J.T. Dalton, Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm. Res. 24(2), 328-35 (2006).

245.         C. E. Bohl, Z. Wu, D. D. Miller, C. E. Bell, J. T. Dalton, Crystal structure of the T877A human androgen receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design.  J. Biol. Chem. In press 2007.

246.         W. Li, Z. Wang, V. Gudududru, B. Zbytek, A. T. Slominski, J. T. Dalton and D. D. Miller, Structure Acitivity Rleationship Studies of Arylthazolidine Amides as Selective Cytotoxic Agents for Melanoma, Anticancer Research, 27, 883-888 (2007).

247.         M. L. Mohler, R. Narayanan, Y. He, D. D. Miller, and J. T. Dalton, Hydroxysteroid Dehydrogenase (17b-HSD3;, 17b-HSD5, and 3a-HSD3) Inhibitors: Extragonadal Regulation of Intracellualar Sex Steroid Hormone Levels, Recent Patents on Endrocrine, Metabolic & Immune Drug Discovery in press (2007).

248.         W. Li, Y. Yu, Z. Wang, J. T. Dalton, and D. D. Miller, Synthesis and Antiproliferative Acitivity of Thiazolidine Analogs for Melanoma, Bio. Med. Chem. Lett. In press (2007).

249.         M. L. Mohler, Y. He, Z. Wu, S. Hong, and D. D. Miller, Dissociated Non-Steroid Gluccocorticoids: Turning Our Untoward Effects, Expert Opinion on Therapeutic Patents, 17(1), 37-58 (2007).

250.     M. L. Mohler, Y. He, Z. Wu, S. Hong, and D. D. Miller, Non-Steroid Gluccocorticoids: Receptor Antagonist: The Race to Replace Ru-486  For Anti-gluccocorticoid Therapy, Expert Opinion on Therapeutic Patents, 17(1), 59-81 (2007).

251.     V. Gududuru, E. Hurh, J. T. Dalton, and D.D. Miller, Synthesis and Antiproliferative Activity of Polyamine Conjugates as Selective Anti-prostate Cancer Agents, In preparation (2007)

252.     S. Vansal, Y. He, V. I. Nikulin, D. D. Miller and D. R. Feller , b₃-Adrenergic Receptor Selective Trimetoquinol Derivatives Increase Uncoupling Protein-1 and Glucose Transporter-4 levels in Immortalized Human Brown Adipocytes, in preparation (2007).

Articles on Education:

1.      D. R. Gourley, C. Rowell, L. Wingate, C. R. Yates, G. K. Gourley, D. D.Miller, V. Vleet Status of PharmD/PhD programs in colleges of pharmacy: the University of Tennessee dual PharmD/PhD program.Am J Pharm Educ., 70(2):44 (2006).

     2.      B. A. Boucher, P. J. Chyka, W. L. Fitzgerald, L. J. Hak, D. D. Miller, R. B. Parker, S. J. Phelps, G. C. Wood, D. R. Gourley.  A comprehensive approach to faculty development. Am. J. Pharm. Educ. 70(2):27 (2006).

B.     Books and Book Chapter (Published/In-Print)

 D. D. Miller, R. W. Brueggemeier, and J. T. Dalton, in Principles in Medicinal Chemistry, Adrenal Corticosteroids, W.O. Foye, Ed., Lea and Febiger, Phil., PA, Chapter 33, in press (2007).

R. W. Brueggemeier, D. D. Miller, and J. T. Dalton, in Principles in Medicinal Chemistry, Men’s Health, W.O. Foye, Ed., Lea and Febiger, Phil., PA, Chapter 29, 685-717 in press (2007).

 C.         Abstracts

307.          J. Hwang, J. Yang, M. Mohler, J. Dalton, and D. D. Miller, Synthesis and Testing of bothe reversible and Irreversible Selective Androgen Receptor Modulators (SARMs) Abstract The 231^th ACS National Meeting, Atlanta, GA , March-26-30, (2006).

 308.     J.D. Kearbey, D.N. Parke, R. Narayanan, J. Okolicany, D.D. Miller, and J.T. Dalton.  Preclinical Pharmacology of a Novel Osteoanabolic Tissue Selective Androgen Receptor Modulator. The Endocrine Society, Boston, Abstract # P3-64, June 2006.

309.     R .Narayanan, C.E. Bohl, J.D. Kearbey, C.C. Coss, D.D. Miller, and J.T. Dalton. Molecular Mechanism for the Tissue Selectivity of a Novel Non-Steroidal Selective Androgen Receptor Modulator: Genome-Wide Mapping of Androgen Receptor Binding Sites. The Endocrine  Society, Boston, Abstract # OR49-1, June 2006.

310.     Z . Wang, Y. Lu, V. Gududuru, B . Zbytek, M.A.  Zmijewski, A.T. Slominski, J.T.  Dalton, D.D. Miller, and W.  Li.  Synthesis and SAR Studies of novel thiazolidine analogs for melanoma. Proceedings of the American Association for Cancer Research, Los Angeles, Abstract #3963, April 17, 2007.

311..    J. Eswaraka., C. Barrett., J. Kearbey., C.Coss., S.S Hong., D. Miller., J. Dalton Discovery and Preclinical Characterization of GTx-103: A Novel SERM useful for alleviating  hot flushes. Proceedings of the European Molecular Biology Association conference on Nuclear Receptors: Structure and Function in Health and Disease, Gardone Riviera, Lake Garda, Italy, #PII.53, page 57, May 2-5, 2007.

 312.    Z. Wang, Y.Lu, V. Gududuru, B. Zbytek, M. A. Zmijewski, A. T. Slominski, J. T. Dalton, D. D. Miller, W.Li, Synthesis and SAR Studies of Novel thiazolidine analogs for melanoma, 2007, AACR annual meeting, Los Angeles, California, April 13-18 Abstract 3963.

 313.     Z. Wang, Y.Lu, V. Gududuru, B. Zbytek, A. T. Slominski, J. T. Dalton, D. D. Miller, W.Li, SAR Studies of Arylthaizolidine Amides As Selective Cytotoxic Agents for Melanoma, Abstract 9, 34th Annual MALTO meeting at University of Louisiana, Monroe, LA , May 20-22 (2007).

 314.     K. Zeng, I. Rakov, K. Emmons, C.R. Yates, and D.D. Miller, Design, Synthesis and Biological Evaluation of Quinic Acid Derivatives As New Anti-inflammatory Agents, Abstract 18, 34th Annual MALTO meeting at University of Louisiana, Monroe, LA , May 20-22 (2007).

 315.          J. Chen, Z. Wang, Y. Lu, D.D. Miller, and Wei Li, Synthsis and Anti-melanoma Research of 2-Arylimidazole-4-carboxylic Acid Amides and 2-Arylimidazoine-4-carboxylic Acid Amides, Poster 1, 34th Annual MALTO meeting at University of Louisiana, Monroe, LA , May 20-22 (2007).

 316.     K. Zeng, I. Rakov, K. Emmons, C.R. Yates, and D.D. Miller, Design, Synthesis and Biological Evaluation of Quinic Acid Derivatives As New Anti-inflammatory Agents, Abstract 18, 34th Annual MALTO meeting at University of Louisiana, Monroe, LA , May 20-22 (2007).

 317            Chen, Z. Wang, Y. Lu, D.D. Miller, and Wei Li, Synthsis and Anti-melanoma Research of 2-Arylimidazole-4-carboxylic Acid Amides and 2-Arylimidazoine-4-carboxylic Acid Amides, Poster 1, 34th Annual MALTO meeting at University of Louisiana, Monroe, LA , May 20-22 (2007).

 318.            S. Ramagiri, R. Gupte, I. Rakov, C. R. Yates and D. D. Miller, Chiral Recognition of Phthaloylglutamic Acid and its Derivatives by Electro Spray Ionizaion and Matrix Assisted Laser Desorption Techniques, American Society of Mass Spectrometry, ACMS 6515, Indianapolis, IN, June 2-7(2007).

 319.            M. G. Decuypere, I. Rakov, D. D. Miller and M. S. Ledoux, Regional Concentrations of (R) salsolinol, (S)salsolinol and their Methyl Derivatives in Mammalian Brain, Neuroscience, May 15 (2007).

 320.            L. Zhu, Y. Lu, D. D. Miller and R. I. Mahato, Synthesis and Characterization of Pyridinium Cationic Lipids for Nucleic Acid Delivery,  AAPS meeting, Abstract, San Diego, CA, to be presented Nov.(2007).

 321.     K. Zeng, I. Rakov, K. Emmons, C.R. Yates, and D.D. Miller, Design, Synthesis and Biological Evaluation of Quinic Acid Derivatives As New Anti-inflammatory Agents, AAPS meeting, Abstract, San Diego, CA, to be presented Nov.(2007).

D.    Invited Oral Presentations (Title; Audience; Date and Place of Presentation)

 Duane D. Miller, “ Search for Reversible and Irreversible SARMs” Gordon Conference, New Hampshire, August 7, 2006.

 Duane D. Miller “ A New Product for Males! SARMs” , Chemistry Department, University of Memphis, Memphis TN,  February 27, 2007.

 Duane D. Miller “ A New Product for Males! SARMs” , Chemistry Department, University of Memphis, Memphis TN,  February 27, 2007.

 Duane D. Miller “Prostate Cancer and SARMs,” University of Tennessee Cancer Institute, Memphis TN, April 2, 2007.  

      E.  Patents/Licensed Products

 Dalton, James T.; Miller, Duane D..   Selective androgen receptor modulators and method of use thereof.    U.S. Pat. Appl. Publ.  (2007),     114pp., Cont.-in-part of U.S. Ser. No. 355,187.  CODEN: USXXCO  US  2007123563  A1  20070531  AN 2007:593997 .

Dalton, James T.; Barrett, Christina; He, Yali; Hong, Seoung-Soo; Miller, Duane D.; Mohler, Michael L.; Narayanan, Ramesh; Wu, Zhongzhi.   Nuclear receptor binding agents.    PCT Int. Appl.  (2007),     216pp.  CODEN: PIXXD2  WO  2007062230  A2  20070531  AN 2007:592162 .

Dalton, James T.; Miller, Duane D..   Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators.    PCT Int. Appl.  (2007),     85pp.  CODEN: PIXXD2  WO  2007027582  A2  20070308  CAN 146:288495  AN 2007:257483.

Dalton, James T.; Miller, Duane D.; He, Yali; Yin, Donghua.   Preparation of arylamides as selective androgen receptor modulators.    U.S. Pat. Appl. Publ.  (2006),     22pp., Cont.-in-part of U.S. Ser. No. 62,752.  CODEN: USXXCO  US  2006287547  A1  20061221  CAN 146:62470  AN 2006:1342401.

 Dalton, James T.; Miller, Duane D.; He, Yali; Yin, Donghua.   Preparation of arylamides as selective androgen receptor modulators.    U.S. Pat. Appl. Publ.  (2006),     23pp., Cont.-in-part of U.S. Ser. No. 125,159.  CODEN: USXXCO  US  2006276540  A1  20061207  CAN 146:27635  AN 2006:1286265.

 Dalton, James T.; Miller, Duane D.; Steiner, Mitchell S.; Veverka, Karen A.   Treating androgen decline in aging male (ADAM)-associated conditions with propanamide derivative selective androgen receptor modulators (SARMs).    U.S. Pat. Appl. Publ.  (2006),     37pp., Cont.-in-part of U.S. Ser. No. 683,161.  CODEN: USXXCO  US  2006276539  A1  20061207  CAN 146:20308  AN 2006:1286111.

 Miller, Duane D.; Tigyi, Gabor J.; Gududuru, Veeresa; Fujiwara, Yuko; Baker, Daniel; Walker, Michelle D.; Durgam, Gangadar Good.   Acetal phosphate-derived LPA mimics, PPAR  activators, and autotaxin inhibitors.    U.S. Pat. Appl. Publ.  (2006),     21pp.  CODEN: USXXCO  US  2006270634  A1  20061130  CAN 146:20341  AN 2006:1256491.

 Steiner, Mitchell S.; Veverka, Karen A.; Miller, Duane D..   Compositions comprising 5 -reductase inhibitors and selective androgen receptor modulators.    U.S. Pat. Appl. Publ.  (2006),     26pp.  CODEN: USXXCO  US  2006258628  A1  20061116  CAN 145:495652  AN 2006:1204621.

 Dalton, James T.; Miller, Duane D.; Marhefka, Craig A.; Gao, Wenqing.   Selective androgen receptor modulators and methods of use thereof.    U.S. Pat. Appl. Publ.  (2006),     15pp., Cont.-in-part of U.S. Ser. No. 462,837.  CODEN: USXXCO  US  2006241180  A1  20061026  CAN 145:449242  AN 2006:1124521.

 Dalton, James T.; Miller, Duane D.; He, Yali; Yin, Donghua.   2-Hydroxy-2-methylpropanamide derivative selective androgen receptor modulators and methods of therapeutic use thereof.    U.S. Pat. Appl. Publ.  (2006),     34pp., Cont.-in-part of U.S. Ser. No. 220,414.  CODEN: USXXCO  US  2006229362  A1  20061012  CAN 145:389398  AN 2006:1070288.

 Dalton, James T.; Miller, Duane D.; Steiner, Mitchell S.; Veverka, Karen A.   Treating wasting disorders with selective androgen receptor modulators.    U.S. Pat. Appl. Publ.  (2006),     12 pp., Cont.-in-part of U.S. Ser. No. 146,427.  CODEN: USXXCO  US  2006111441  A1  20060525  CAN 144:460891  AN 2006:494216.

 Dalton, James T.; Miller, Duane D.; Veverka, Karen A.   Selective androgen receptor modulators (SARMs) and their therapeutic use.    U.S. Pat. Appl. Publ.  (2006),     39 pp., Cont.-in-part of U.S. Ser. No. 961,380.  CODEN: USXXCO  US  2006035965  A1  20060216  CAN 144:205824  AN 2006:149914.

 Miller, Duane D.; Dalton, James T.; Gududuru, Veeresa; Hurh, Eunju.   Thiazolidine derivatives and other compounds exhibiting inhibition of cell proliferation, methods of preparation, and use in the treatment of cancerous conditions.    U.S. Pat. Appl. Publ.  (2006),     45 pp., Cont.-in-part of U.S. Ser. No. 992,175.  CODEN: USXXCO  US  2006014740  A1  20060119  CAN 144:143031  AN 2006:52512.

Dalton, James T.; Miller, Duane D.; Yin, Donghua; He, Yali.   N-Aryl-3-aryloxy-2-hydroxy-2-methylpropanamide derivatives as selective androgen receptor modulators, which are useful for male contraception and treatment of a variety of hormone-related condition, and pharmaceutical composition, their synthesis and large-scale preparation.    U.S. Pat. Appl. Publ.  (2006),     31 pp., Cont.-in-part of U.S. Ser. No. 863,524.  CODEN: USXXCO  US  2006009529  A1  20060112  CAN 144:108102  AN 2006:36789.

Dalton, James T.; Miller, Duane D.; Veverka, Karen A.   Formulations comprising selective androgen receptor modulators.    U.S. Pat. Appl. Publ.  (2006),     20 pp., Cont.-in-part of U.S. Ser. No. 371,213.  CODEN: USXXCO  US  2006004042  A1  20060105  CAN 144:94394  AN 2006:13083.

“Real-time Polymerase Chain Reaction-Based Genotyping Assay for Single Nucleotide Polymorphism”, Inventors: C. Ryan Yates, Duane D. Miller, Dick R. Gourley, and Pengfei Song, U.S. Patent 7,018,816 B2, issued March 28, 2006.

“Thiazolidine derivations and other compounds exhibiting inhibition of cell proliferation, methods of preparation, and use in the treatment of cancerous conditions”, D. Miller, J. Dalton, V. Gududuru, and E. Hurh, U.S. Patent 992,175 issued 2006.

“n-Aryl-3-aryloxy-2-hydroxy-2-methylpropanamide derivates as selective androgen receptor modulators, which are useful for male contraception and treatment of a variety of hormone-related condition, and pharmaceutical compositon, their synthesis and large-scale preparation”. J. Dalton, D. Miller, D. Yin, and Y. He, U.S. Patent 863,524 issued in 2006.

“Formulations comprising selective androgen receptor modulators”. J. Dalton, D. Miller, and K. Veverka, U.S. Patent 371,213 issued in 2006. 

“Selective androgen receptor modulators (SARMs) and their therapeutic use”, J. Dalton, D. Miller, and K. Veverka, U.S. Patent 961,380 issued 2006.

“b₃-Adrenoceptor Agonists, Agonist Compositions and Methods of Using”, Inventors: Duane D. Miller and Dennis R. Feller, US 7,119,103,B2 (Oct. 10, 2006).

 3.  Licensed

 IV.      GRADUATE STUDENTS/POST-DOCTORAL TRAINING

A.     Mentor for Graduate Students Currently in the Program

1.                1. Kui Zheng, First Year Ph.D. student, Proposed Dissertation:  New Antiinflammatory Agents
Major Professor: Dr. Duane D. Miller

                   2.   Renuka Gupte, Fourth Year Ph.D. student, Proposed Dissertation:  LPA Agonists and Antagonist SAR
Major Professor: Dr. Duane D. Miller

B.  Mentor for Pharm.D./Ph.D. Students Currently in the Pharm.D. Program

C.  Postdoctoral Fellows

Igor Rakov
Research: New Tricyclic SARMS and N-Substituted Analogs of THI’s

Verresa Gududuru
Research: 5- and 7-Membered Ring Analogs of Potent THI’s and LPA agonist and antagonists

          Vipin Nair
Research: SARMs with B ring modifications

          Suni Mustafa
Research: SARMS with A ring modifications

          Renuka Patil
Research: SARMS with carboxylic acids and cyclohexyl A ring

          Dong Jin Hwang
Research: Chiral SARMS

          Yan Lu
Research: Thiazolidines to treat melanoma

          Charles Duke
New anticancer agents designed around bisindoles

          Shivaputra Patil
New SARMs and new potassium channel blockers

      D.  Graduate Students Who Completed Work This Year

          E.   Mentor for University of Tennessee Summer Undergraduate Research Interns 
                      Steven Moore New Drugs for Prostate Cancer
                 Andy Bernard PharmD/PhD laboratory rotation

V.  SERVICE

      A.  UT Committees (Department, College, University, including graduate student committees):

                  Graduate Research Committee
                        Faculty Development Committee
                        University Patent Committee
                        Search Committee for Vice Chancellor for Research

B.     Associational Offices/Directors (National, State, Boards, NIH Study Sections; Editorial Boards; Consulting; Advisory Boards, etc.)

C.  Community Service         

   VI.    HONORS, AWARDS, SPECIAL RECOGNITION, ETC.

          A.  UT
          B.  Other

  VII.   NEW PROGRAMS and SIGNIFICANT ACHIEVEMENTS
  VIII.    MINORITY RECRUITMENT EFFORTS

  IX.    ACHIEVEMENT OF GOALS FOR  2005/2006
            Teaching and Training Goals Achieved
            Presented lectures in the both PharmD.

          Research and Scholarly Activity Goals Achieved

      Published 20 manuscripts, presented 15 abstracts, wrote two book chapters for Foye, had ten patents and graduated 3 PhD students.

           Grant Applications Submitted in 2006/2007 (Funded/Not Funded)

           Pending Support for Duane Miller
               Principle Investigator:  Duane Miller
            Dates: 09/01/07-8/31/2011
            Source: National Institutes of Health
            Title: Novel Pharmacophores for the Androgen Receptor
            Annual Direct Cost: $250,000 for $1 million
            Percent Effort: 10%

              Service Goals Achieved

      X.   GOALS FOR 2006/2007

        Teaching and Training

Teach the Medicinal Chemistry Course to 200 students. This will be the largest class I have ever taught.

            I plan to work with my graduate students and postdoctorals and meet with the on a weekly basis.

        Research and Scholarly Activities
               1, I plan to continue our NIH grant research in prostate cancer
               2. Continue to work on contracts with ED laboratory to find a drug for the treatment of glioma
               3. Work with RxBio to find a drug to prevent the side effects of radiation and chemotherapy
               4. Plan to work with GTx to get a new class of agents “SARMs” to the market
               5. Work with GRX to get a new method for checking genetics before putting individuals on anticoagulants
               6. Start a new project in order to find a new anti-inflammatory agent that will work by a new mechanism.
               7. Plan to submit 5 new patent.
               8. Write 10 new manuscripts
               9. Write three new grants.

      Service
                  Serve as Chairman of our Department of Pharmaceutical Sciences
              Serve on College and University committee to carry out the mission of the University
              Work with MALTO our regional graduat student meeting to strengthen our research in this area (we have invited Kentucky to participate in this group for next year). We are beginning plans for the 2009 meeting in Memphis.
              Purchase new equipment for the department
              Hire a new faculty member in pharmaceutics. This will involve developing an advertisement for the position. Set up a search committee. Get the start up of our new Hyde Scholar off to a good start
              Evaluate the graduate program exam process
              Streamline the course requirements in the graduate program(specifically the Medicinal Chemistry Group).
              Initiate a better tenure and promotion process by evening up the number of members from the two Departments on the Tenure and Promotion Committee.
              Set up and work with the GRI consortium at the University of Cincinnati, Ohio.
              Work on getting new staff members and work on retention of current staff.

 Last Updated on 09/04/2007 by Webmaster